Moderna CEO and AstraZeneca Official Reveal Shocking

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
326
Moderna CEO and AstraZeneca Official Reveal Shocking Secrets to COVID Vaccines After Romanian MEP Cristian Terheș Grills Them

On Monday, Romanian Member of the European Parliament Cristian Terheș grilled Moderna CEO Stéphane Bancel and AstraZeneca executive vice-president Iskra Reic surrounding the safety and efficacy of the vaccines and overly secretive contracts.

Several concerns were asked by MEP Terhes of the executives, such as whether or not they had decoded the DNA of the COVID virus, why they did not take responsibility for the side effects from the vaccines, and when they would release the unredacted contracts with the European Commission.

The first set of questions was for both AstraZeneca and Moderna. Below are the questions asked by Terhes:

First question: I would like to know the date, if possible, when you decoded the entire DNA sequence of this virus or did you rely solely on the sequence provided by the Chinese government?

Second question: Have you tested whether the vaccine stops the spread of the virus or not? Because the data clearly shows that your products are not stopping the spread of this virus.

Third question: Have you had people die during the human trials, and if so, what was the disease they died from?

The second set of questions was directed to Moderna CEO Bancel, below is the excerpt:

You stated here that you relied on the sequence provided to you by the Chinese government when you developed your vaccine. I have here an answer from EMA, which shows for every vaccine the kind of tests that were done.
So in the case of Moderna, for example, you provided data showing that you tested these vaccines since 2017, 2018, and 2019. So how are you able to test these vaccines back then when we found out about this virus in December of 2019?

The contract you mentioned here that there are some secrets or some confidential information in these contracts that should protect your interests. Now, the question that I addressed to you is, what about the interests of us and the interests of the European citizens?

Because this is how some of the pages from the contract between Moderna and the European Commission is showing. So I’m asking you, do you think this is fair to all of us to talk about these vaccines, to talk about boosters, to talk about medical products when we don’t know the clauses of these contracts? So the direct question to you, Mr. Bonsel, is when are you going to fully publish the contracts that you have both with the European Commission and with the member states of the European Union?

Another question, the issue of liabilities. You were asked by our colleagues here about the liabilities and you avoided to answer this question. So my question is why are you pushing the liabilities on the state and on the people who receive these vaccines? I think I might have adverse effect, why do you get all the profits?

Nevertheless, the bivalent boosters. This is the last question. You just stated here that these boosters were requested by the US government who also approved the boosters without trials on humans.

So I’m asking you, do you think this is fair? Do you think we can go and ask the European citizens to be vaccinated with some medical products that were not properly tested or not at all tested in humans?

In their responses regarding liability, executives of Moderna and AstraZeneca said that they produced the vaccines at the request of the states and governments, who asked them to make the vaccines quickly, therefore they sought protection from them for payment of possible damages and compensations, according to MEP’s Facebook post.

“On liability for adverse effects, as all manufacturers have done, we wanted, governments wanted quick approval of a vaccine. And so for a conditional approval, it was important to give us some guarantees in terms of [compensation/damages], because we cannot have our cake and eat it too. They wanted the vaccine quickly. They didn’t give the manufacturers time to have long-term studies because of the nature of a pandemic,” Moderna CEO Stéphane Bancel answered the question MEP Cristian Terheș.

“The liability and indemnification clause was discussed and agreed upon with many governments around the world because everyone wanted to see how we could speed up the production and delivery of vaccines. And, again, as I mentioned earlier, this is considered to be standard practice in emergency situations, and equally [the practice] that protects and supports everyone to move forward with the greatest speed and to do the best they can in terms of production and manufacturing [vaccines],” AstraZeneca executive vice president Iskra Reic answered the same question.

Bancel also admitted that Moderna used the sequence published by the Chinese government online and tested by many scientists in academic labs and government labs for the design of the vaccine.

Back in March, Pfizer CEO Albert Bourla admitted during his interview with WaPo that the “mRNA vaccine” technology was not sufficiently proven when they launched it. He said the experts “convinced him” but he wasn’t sure. He said they’ve been working for the mRNA since 2018.

https://www.thegatewaypundit.com/2022/09/must...es-grills/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Indico Breach May Expose Thousands to Identity Theft

Updated Category News Views 4

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

Continue Reading
BC Mosaic App Store Unlocks New Tools for Researchers

Updated Category News Views 2

Unleashing Innovation Through Specialized Apps Oh boy, it's about time someone shook things up in the research game. BC Platforms has rolled out the BC Mosaic App Store, a move that's got research types buzzing from Zurich to... well, anywhere healthcare pokes its head. These guys aren't just throwing out some generic, run-of-the-mill tools. No sir, they've created a...

Continue Reading
Qapture Expands Global DeFi Reach with Key Acquisitions

Updated Category News Views 0

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

Continue Reading
stackArmor Secures FedRAMP High: A Strategic Milestone

Updated Category News Views 2

stackArmor: Carving a Niche in Federal Cybersecurity Hey, not every day you wake up to find a company carving its niche in federal cybersecurity quite the way stackArmor is doing. They've recently got their hands on that elusive FedRAMP High authorization for The Armory. What's this mean in English? Well, for starters, these guys are showing they're serious about...

Continue Reading
Power Solutions Litigations Prompt Investor Caution

Updated Category News Views 0

A Storm Brews Over Power Solutions International Look, if you're holding Power Solutions International (NASDAQ:PSIX) in your portfolio, it's time to perk up. The air's thick with talk that Kuehn Law, the firm with a head for shareholder litigation, is on their case. They're poking around, seeing if some executives got a little too creative with the truth. Word on the...

Continue Reading
RMX's QuantrusX™: Transforming Edge Intelligence

Updated Category News Views 1

The Edge Gets Real RMX Industries is tearing up the old rulebook of intelligence with their latest move. They’re calling it Real-World Intelligence, and right off the bat, RMX (OTCQB:RMXI) makes it clear they're not here to sell us some dusty data center illusion anymore. They're putting intelligence where the action is, at the physical edge, and that's something you...

Continue Reading
HIMS Faces Class Action: Investors Eye Leadership

Updated Category News Views 0

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

Continue Reading
AEC Firms Revamp Strategies Amid Talent Tug-of-War

Updated Category News Views 2

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Continue Reading
Battling Razor Bumps: Breaking a Persistent Cycle

Updated Category News Views 3

Understanding Razor Bumps: More Than a Cosmetic Annoyance Crossing Great Neck this morning, I stumbled across a curious release from Laser by Aleya. Apparently, the problem with those pesky razor bumps plaguing many isn't just skin-deep. For some, especially those with coarse or curly hair, each razor stroke starts a relentless cycle of irritation that's as grinding as...

Continue Reading
iRobot's Roomba Max 875: The Ultimate Cleaning Machine

Updated Category News Views 3

Roomba Max 875 Combo: Setting a New Standard Alright, folks, iRobot's at it again—unleashing what they tout as their beefiest cleaner to date, the Roomba Max 875 Combo Robot. It's a name that might twist your tongue, and this technological titan's feature list is equally complex. You know the routine with these fancy gadget launches: big promises, shiny features, but...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Affordable Homes Coming to Sable Run

Updated Category News Views 150

Explore Sable Run: Affordable Living Awaits Century Communities is thrilled to introduce Sable Run, a vibrant new community set to offer accessible homeownership options for families and individuals. With prices beginning in the $300s, Sable Run intends to fulfill the growing demand for modern and affordable housing. Stunning Home Designs This community features two...

Continue Reading
IM Alliance Conference Promises Revolutionary Insights in Healthcare

Updated Category News Views 116

IM Alliance Conference Promises Revolutionary Insights This year, the Independent Medical Alliance (IMA) is preparing to host its 4th Annual Conference with a pivotal theme that speaks volumes about the future of healthcare. Titled "Honest Medicine: Redefining Health," this event will take place from April 4-6 in a bustling setting. With a robust lineup of leading medical...

Continue Reading
Mobile Application Market Surge Driven by AI and Smartphone Trends

Updated Category News Views 259

Transformative Growth in Mobile Application Market The global mobile application market is anticipated to show substantial growth, with a predicted increase of USD 2.63 trillion from 2025 to 2029. The remarkable growth trajectory is attributed to the expanding smartphone penetration and advancements in technology, particularly artificial intelligence (AI) and machine...

Continue Reading
Orezone Gold Fully Exercises Over-Allotment Option for Growth

Updated Category News Views 114

Orezone Gold's Ambitious Expansion Plan Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) recently made headlines with its bold move to fully exercise its over-allotment option related to a significant financing deal. By doing so, they secured an additional 6,402,450 common shares at a price of C$0.82 per share, which generated gross proceeds of C$5,250,009. Strategic Use...

Continue Reading
ASP Isotopes Inc. Announces New Public Common Stock Offering

Updated Category News Views 91

ASP Isotopes Inc. Public Offering Announcement In a significant move, ASP Isotopes Inc. (NASDAQ: ASPI) has announced the pricing of its underwritten public offering of common stock. The company plans to sell a total of 2,395,000 shares, priced at $6.75 each. This offering is projected to generate approximately $16.2 million for ASP Isotopes, before accounting for...

Continue Reading